GlaxoSmithKline: EU approves asthma drug for children
(CercleFinance.com) - The European Commission has approved GlaxoSmithKline's monoclonal antibody Nucala for treating children with severe asthma, the British company said on Thursday.
Brussels has granted marketing authorisation for Nucala as an add-on treatment for severe refractory eosinophilic asthma in pediatric patients between 6 and 17 years old.
This means that Nucala is now approved for use in both adult and pediatric patients in the 31 European countries covered by the European Medicines Agency (EMA).
Asthma is the most common chronic disease in children.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Brussels has granted marketing authorisation for Nucala as an add-on treatment for severe refractory eosinophilic asthma in pediatric patients between 6 and 17 years old.
This means that Nucala is now approved for use in both adult and pediatric patients in the 31 European countries covered by the European Medicines Agency (EMA).
Asthma is the most common chronic disease in children.
Copyright (c) 2018 CercleFinance.com. All rights reserved.